Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | LITAF | Q99732 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016873 | 0.89 | AAK1 (0.39) | AAK1KDM5ACMA1ADORA3ADORA2A | |
| SCHEMBL22016877 | 0.87 | ADORA3 (0.41) | AAK1KDM5ACMA1ADORA3ADORA2A | |
| SCHEMBL24437016 | 0.77 | CMA1 (0.38) | AAK1KDM5ACMA1ADORA3ADORA2A | |
| SCHEMBL22016215 | 0.77 | CMA1 (0.38) | AAK1KDM5ACMA1ADORA3ADORA2A | |
| SCHEMBL13819107 | 0.77 | ADORA3 (0.53) | AAK1KDM5AADORA3ADORA2AADORA1 | |
| SCHEMBL22017691 | 0.75 | GRM4 (0.44) | CMA1ADORA3ADORA2AADORA1KAT2B | |
| SCHEMBL13322657 | 0.71 | MAPK14 (0.40) | ADORA3ADORA2AADORA1DYRK1A | |
| SCHEMBL13322656 | 0.71 | HPD (0.42) | ADORA3ADORA2AADORA1DYRK1A | |
| SCHEMBL22016239 | 0.71 | ADORA3 (0.43) | AAK1KDM5ACMA1ADORA3ADORA2A | |
| SCHEMBL12383079 | 0.71 | MAOA (0.42) | ALDH1A1CDK4CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | AAK1 3444/4885KDM5A 2386/4885CMA1 146/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | AAK1 2419/4885KDM5A 3004/4885CMA1 1134/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | AAK1 3444/4885KDM5A 2386/4885CMA1 146/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | AAK1 2419/4885KDM5A 3004/4885CMA1 1134/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | AAK1 3444/4885KDM5A 2386/4885CMA1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.